Abstract: The invention is directed to Muramyl Dipeptide (MDP) derivative compounds of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof: wherein, R can be a linear or branched alkyl, an aryl, a substituted aryl, or an alkoxy alkyl. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are particularly useful as adjuvants in vaccines.

Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.

Abstract: Invention provides novel rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention are stable liquid rotavirus vaccine formulations for oral administration.

Abstract: The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost-effective and affordable, especially for lower-middle income and low-income countries.

Abstract: The present invention is based on the isolation of a gene coding for streptokinase from Streptococcus equisimilis (ATCC 9542), its cloning, and expression in E. coli. Two different strategies were carried out for the production of enzymatically-active streptokinase. In the first strategy, streptokinase was expressed as an inclusion body without its signal sequence followed by purification, solubulization, and renaturation to obtain an active preparation. The purified enzyme was formulated and lyophilized. In the second strategy, enzymatically-active streptokinase is secreted into the culture medium. The enzyme was purified, formulated and lyophilized.